查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087636

潰瘍性大腸炎市場：2026-2032年全球市場預測（依治療方法、給藥途徑、類型、治療階段、疾病嚴重程度、病患類型及通路分類）

Ulcerative Colitis Market by Therapy Type, Route of Administration, Type, Line Of Therapy, Disease Severity, Patient Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，潰瘍性大腸炎市場規模將成長至 155.1 億美元，複合年成長率為 8.41%。

主要市場統計數據
基準年 2025 88.1億美元
預計年份：2026年 95.4億美元
預測年份 2032 155.1億美元
複合年成長率 (%) 8.41%

潰瘍性大腸炎是一種涉及大腸和直腸的慢性發炎性腸道疾病，其特徵是反覆出現腹瀉（伴隨血便）、便急、腹痛、疲倦和貧血等症狀。隨著診斷技術的進步、生物製藥和小分子藥物應用的增加，以及治療目標從控制症狀轉向內視鏡治癒、實現非荷爾蒙依賴性緩解和長期預防切除術，市場環境正在擴大。

已開發市場發炎性腸道疾病盛行率的顯著上升以及新興工業化國家發病率的加速成長，推動了市場需求。根據美國疾病管制與預防中心（CDC）統計，美國有數百萬成年人患有發炎性腸道疾病，同行評審的流行病學文獻也一致表明，北美和歐洲的盛行率很高，亞太地區、中東和拉丁美洲的盛行率也在迅速上升。

對於產業領導者而言，潰瘍性大腸炎市場的特徵是創新密集。抗TNF製劑、整合素抑制劑、IL-12/23和IL-23路徑標靶療法、 Janus激酶抑制劑以及鞘氨醇-1-磷酸受體調變器正在重塑治療方案、與保險公司的談判以及患者的預期。競爭優勢越來越依賴差異化的療效、安全性、便利性、可負擔性、真實世界數據以及貫穿患者整個治療過程的數位化支持。

潰瘍性大腸炎治療環境的變革性變化

潰瘍性大腸炎的治療模式正經歷著從階梯式治療轉變為更個人化、目標導向型治療的重大轉變。胃腸病學指南越來越強調利用內視鏡檢查、糞鈣衛蛋白和C反應蛋白（CRP）等生物標記以及檢驗的症狀評分進行客觀的疾病評估。這正在改變治療方案的選擇、監控和調整方式。

人工智慧對潰瘍性大腸炎的累積影響

人工智慧 (AI) 正在對潰瘍性大腸炎的研究、診斷、治療最佳化和商業化等各個領域產生累積影響。在臨床開發中，AI 驅動的分析可以改善電子健康記錄篩檢、臨床實驗入合格、方案可行性模擬和臨床實驗選擇。這在潰瘍性大腸炎領域尤其重要，因為該領域患者病情嚴重程度、先前高階治療經驗和疾病活動度的波動性都使得受試者招募變得複雜。

關於潰瘍性大腸炎的關鍵區域性見解

北美仍然是潰瘍性大腸炎最成熟的地區之一，這得益於發炎性腸道疾病的高發病率、完善的胃腸病學基礎設施、生物製藥的廣泛應用以及針對專科藥物的成熟報銷機制。美國透過臨床試驗、學術性發炎性腸道疾病（IBD）中心、法規核准以及真實世界數據（RWE）的產生來推動區域創新，而加拿大則受益於系統化的公共和私人報銷體系、省級准入決策以及活躍的專科醫生網路。

針對七國集團、歐盟、金磚國家、東協、海灣合作理事會和北約的關鍵群體特定見解。

由於診斷率高、處方實踐先進、支付方應對力迅速以及臨床試驗活動活躍，七國集團（G7）是潰瘍性大腸炎商業化領域最活躍的叢集。美國、加拿大、日本、德國、法國、義大利和英國在產品上市流程、衛生經濟學證據的產生、臨床指南的影響以及上市後監測方面發揮核心作用。

潰瘍性大腸炎的關鍵國家概況

就治療強度而言，美國作為單一國家擁有最大的市場機會，這得益於其炎症性腸病的高發病率、已通過核准療法的快速分銷、健全的專科藥房管道以及競爭激烈的市場環境。加拿大雖然規模較小，但也是一個成熟的市場，公共處方藥目錄、私人保險和省級政府的決策都會影響藥物的可及性。墨西哥和巴西是拉丁美洲的主要市場，在這些國家，私部門的用藥量超過了公部門，公共採購也會影響治療藥物的供應。

為行業領導者提供的實用建議

產業領導者應優先考慮差異化證據，這些證據需能證明在真實世界的潰瘍性大腸炎患者群體中，藥物能夠持續緩解臨床症狀、促進黏膜癒合、有效減重類固醇用量、確保安全性並改善患者生活品質。隨著更多先進療法競相開發類似患者群體，比較研究、註冊登記數據、患者報告結局以及與支付方相關的終點指標變得日益重要。

調查方法

本執行摘要採用二手調查方法，並遵循市場情報最佳實務編寫而成。資訊來源包括公開的法規核准文件、臨床指南趨勢、流行病學研究結果、同行評審的發炎性腸道疾病文獻、政府衛生相關資訊來源、衛生技術評估 (HTA) 趨勢以及已發表的關於獲得專科醫療服務的證據。

結論

潰瘍性大腸炎市場正朝著競爭更加激烈的方向發展，治療效果至關重要。人們對該疾病的認知不斷提高，先進治療方案不斷湧現，生物相似藥的競爭日益激烈，以及「達標治療」療法的引入，都在改變患者的診斷、治療和後續觀察方式。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章潰瘍性大腸炎市場：依治療類型分類

  • 氨基水楊酸類藥物
    • 美沙拉嗪
    • 柳氮磺胺吡啶
  • 生物製劑
    • 抗整合素
    • IL抑制劑
    • TNF抑制劑
      • Infliximab
      • Adalimumab
      • 戈利木單抗
  • 皮質類固醇
    • 強的松
    • Budesonide
    • Hydrocortisone
  • 免疫調節藥物
    • Azathioprine
    • 6-Mercaptopurine
    • 胺基甲基葉酸
  • 小分子藥物
    • 託法替尼
    • Upadacitinib
  • 外科手術

第8章潰瘍性大腸炎市場：依給藥途徑分類

  • 注射藥物
    • 靜脈
    • 皮下
  • 口服
  • 外用

第9章潰瘍性大腸炎市場：按類型分類

  • 潰瘍性直腸炎
  • 直腸乙狀結腸炎
  • 左側結腸炎
  • 廣泛性結腸炎

第10章潰瘍性大腸炎市場：依治療階段分類

  • 一線治療
  • 第二行
  • 從第三行開始

第11章潰瘍性大腸炎市場：依疾病嚴重程度分類

  • 溫和的
  • 緩和
  • 嚴重

第12章潰瘍性大腸炎市場：依患者類型分類

  • 成人
  • 兒童

第13章潰瘍性大腸炎市場：依通路分類

  • 物理藥房
  • 網路藥房

第14章潰瘍性大腸炎市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章潰瘍性大腸炎市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章潰瘍性大腸炎市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • AbbVie Inc.
  • Abivax SA
  • Ajinomoto Pharmaceuticals Co., Ltd.
  • Amgen Inc.
  • Apotex Inc.
  • AstraZeneca plc
  • Bausch Health Companies Inc.
  • Biocon Limited
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celltrion, Inc.
  • Dr. Falk Pharma GmbH
  • EA Pharma Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Ferring International Center SA
  • Fresenius Kabi AG
  • Galapagos NV
  • Gilead Sciences Inc.
  • Janssen Biotech, Inc. by Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Viatris Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-0335FFDBEF39

The Ulcerative Colitis Market is projected to grow by USD 15.51 billion at a CAGR of 8.41% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.81 billion
Estimated Year [2026] USD 9.54 billion
Forecast Year [2032] USD 15.51 billion
CAGR (%) 8.41%

Ulcerative colitis is a chronic inflammatory bowel disease affecting the colon and rectum, with relapsing symptoms that can include bloody diarrhea, urgency, abdominal pain, fatigue, and anemia. The commercial landscape is expanding as diagnosis improves, biologic and small-molecule adoption rises, and treatment goals shift from symptom control toward endoscopic healing, steroid-free remission, and long-term prevention of colectomy.

Demand is supported by a well-documented rise in inflammatory bowel disease prevalence across industrialized markets and accelerating incidence in newly industrialized economies. The U.S. Centers for Disease Control and Prevention has reported millions of U.S. adults living with inflammatory bowel disease, while peer-reviewed epidemiology literature consistently shows high prevalence in North America and Europe and fast growth in Asia-Pacific, the Middle East, and Latin America.

For industry leaders, the ulcerative colitis market is defined by innovation density. Anti-TNF agents, integrin inhibitors, IL-12/23 and IL-23 pathway therapies, Janus kinase inhibitors, and sphingosine-1-phosphate receptor modulators are reshaping treatment sequencing, payer negotiations, and patient expectations. Competitive advantage increasingly depends on differentiated efficacy, safety, convenience, affordability, real-world evidence, and digital support across the patient journey.

Transformative Shifts in the Ulcerative Colitis Landscape

The ulcerative colitis landscape is undergoing a decisive shift from step-up therapy to more personalized, treat-to-target care. Gastroenterology guidelines increasingly emphasize objective disease assessment through endoscopy, biomarkers such as fecal calprotectin and C-reactive protein, and validated symptom scores. This is changing how therapies are selected, monitored, and switched.

Recent regulatory activity has expanded treatment choice. Approvals for advanced therapies, including sphingosine-1-phosphate receptor modulators, selective Janus kinase inhibitors, IL-23 pathway therapies, and additional oral small molecules, have increased competition beyond traditional anti-TNF biologics. At the same time, biosimilars for established biologics are creating pricing pressure, widening access, and encouraging earlier use of advanced therapy in eligible patients.

Care delivery is also transforming. Home-based administration, specialty pharmacy coordination, remote monitoring, and digital adherence tools are reducing friction in chronic disease management. The most successful market participants are aligning clinical outcomes with patient convenience, payer evidence needs, and health-system capacity constraints.

Cumulative Impact of Artificial Intelligence on Ulcerative Colitis

Artificial intelligence is becoming a cumulative force across ulcerative colitis research, diagnosis, treatment optimization, and commercialization. In clinical development, AI-enabled analytics can screen electronic health records, identify eligible trial populations, simulate protocol feasibility, and improve site selection. This matters in ulcerative colitis, where heterogeneous disease severity, prior advanced therapy exposure, and fluctuating disease activity complicate recruitment.

In clinical practice, computer-aided endoscopy and image analytics are being evaluated to support consistent assessment of mucosal inflammation. AI-based interpretation of colonoscopy and histology images may help standardize scoring systems, reduce inter-reader variability, and support treat-to-target decisions when validated and integrated responsibly.

The commercial impact is also significant. Natural language processing can extract real-world evidence from clinical notes, payer data, and registries, while predictive models can support adherence programs and risk stratification. Industry leaders must balance these benefits with rigorous validation, bias monitoring, privacy protection, cybersecurity readiness, and transparent governance to meet regulatory and clinician expectations.

Key Regional Insights for Ulcerative Colitis

North America remains one of the most mature ulcerative colitis markets, supported by high inflammatory bowel disease prevalence, advanced gastroenterology infrastructure, extensive biologic use, and established reimbursement pathways for specialty medicines. The United States drives regional innovation through clinical trials, academic IBD centers, regulatory approvals, and real-world evidence generation, while Canada benefits from structured public and private reimbursement systems, provincial access decisions, and active specialist networks.

Europe has a high disease burden and a sophisticated access environment shaped by regional regulators, national health technology assessment bodies, and cost-effectiveness requirements. Germany, France, Italy, Spain, and the United Kingdom are central markets, with biosimilar adoption and treatment guidelines influencing prescribing behavior. The European focus on value-based healthcare increases the importance of comparative effectiveness, long-term safety data, patient-reported outcomes, and evidence of steroid-free remission.

Asia-Pacific is the fastest-changing region as ulcerative colitis incidence rises in China, India, Japan, South Korea, Australia, and ASEAN economies. Urbanization, dietary changes, improved diagnostic capacity, and expanding insurance coverage are contributing to broader treatment adoption. Latin America, led by Brazil and Mexico, is gaining momentum as specialty care access improves, though affordability and public-sector procurement remain key constraints. The Middle East, especially Gulf countries, is investing in tertiary care, digestive disease centers, and access to biologics and oral advanced therapies, while Africa remains earlier in market development with substantial unmet needs in diagnosis, specialist availability, endoscopy capacity, and therapy affordability.

Key Group Insights Across G7, EU, BRICS, ASEAN, GCC, and NATO

The G7 represents the highest-intensity cluster for ulcerative colitis commercialization because it combines high diagnosis rates, advanced prescribing, payer sophistication, and dense clinical trial activity. The United States, Canada, Japan, Germany, France, Italy, and the United Kingdom are central to launch sequencing, health-economic evidence generation, guideline influence, and post-marketing surveillance.

The European Union is strategically important because reimbursement decisions are closely tied to comparative clinical benefit, budget impact, biosimilar competition, and real-world outcomes. EU markets also lead biosimilar penetration in many therapeutic classes, making lifecycle management, differentiation, and evidence communication essential. NATO countries overlap with many high-income markets where resilient medicine supply chains, domestic manufacturing capacity, and health-security planning increasingly influence procurement and continuity of care for chronic immune-mediated diseases.

BRICS economies are becoming long-term growth engines for ulcerative colitis care. China and India are expanding diagnosis and access, Brazil supports Latin American demand, and South Africa represents a gateway for selected African markets, while Russia maintains a substantial patient base despite access and geopolitical complexities. ASEAN is at an earlier but rising stage of adoption as gastroenterology infrastructure improves in markets such as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. The GCC is a premium access cluster with strong hospital investment, high use of imported specialty medicines, and increasing focus on local healthcare transformation, specialty centers, and chronic disease management.

Key Country Insights for Ulcerative Colitis

The United States is the largest single-country opportunity by treatment intensity due to high inflammatory bowel disease prevalence, rapid uptake of approved therapies, robust specialty pharmacy channels, and a competitive payer environment. Canada offers a smaller but well-structured market where public formularies, private insurance, and provincial decisions shape access. Mexico and Brazil are key Latin American markets, with private-sector adoption outpacing broader public access and public procurement influencing therapy availability.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine high clinical expertise with disciplined reimbursement review. Germany often provides early post-approval access under European pathways, while the United Kingdom places strong emphasis on cost-effectiveness through health technology assessment. France, Italy, and Spain require strong evidence packages, regional access planning, and alignment with national prescribing guidance. Russia remains a relevant market by population size, but access is affected by procurement structures, reimbursement variability, and geopolitical risk.

China and India are high-potential markets due to large populations, rising diagnosis, and expanding specialty care, though affordability and uneven access remain important. Japan has a mature gastroenterology market with established use of advanced therapies, rigorous regulatory standards, and strong physician engagement in inflammatory bowel disease care. South Korea and Australia demonstrate advanced treatment adoption, high-quality clinical practice, reimbursement pathways for eligible patients, and active participation in global trials, making them important reference markets in Asia-Pacific.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated evidence that demonstrates durable clinical remission, mucosal healing, steroid-sparing benefit, safety, and quality-of-life improvement in real-world ulcerative colitis populations. Comparative studies, registry evidence, patient-reported outcomes, and payer-relevant endpoints are increasingly important as more advanced therapies compete for similar patient segments.

Market access teams should prepare region-specific value dossiers that address biosimilar pressure, budget impact, safety monitoring, and treatment sequencing. Patient support programs should reduce abandonment through education, prior authorization support, adherence tracking, injection or infusion coordination, and collaboration among gastroenterologists, nurses, specialty pharmacies, and payers.

Organizations should invest in precision medicine, biomarker strategies, and AI-enabled evidence generation while maintaining strong governance. Partnerships with IBD centers, digital health providers, and patient advocacy organizations can improve recruitment, adherence, and outcomes. In emerging markets, phased access models, local partnerships, clinician education, and affordability strategies are essential to sustainable expansion.

Research Methodology

This executive summary is developed using a secondary research methodology aligned with market intelligence best practices. Inputs include publicly available regulatory approvals, clinical guideline trends, epidemiology findings, peer-reviewed inflammatory bowel disease literature, government health sources, health technology assessment signals, and published evidence on specialty medicine access.

The analysis emphasizes verified evidence rather than speculative estimates. Regional, group, and country insights are synthesized from documented differences in disease burden, healthcare infrastructure, reimbursement systems, regulatory environments, clinical trial concentration, biosimilar adoption, and specialty medicine access.

Findings are triangulated across clinical, commercial, and policy dimensions to support an evidence-based interpretation. The methodology favors durable market drivers, observable treatment shifts, and validated healthcare trends over short-term promotional claims or unverified projections.

Conclusion

The ulcerative colitis market is entering a more competitive and outcomes-driven era. Rising disease recognition, expanding advanced therapy options, biosimilar competition, and the adoption of treat-to-target care are changing how patients are diagnosed, treated, and monitored.

North America and Europe remain the most mature markets, while Asia-Pacific, Latin America, the Middle East, and selected African countries represent important growth frontiers. Across all regions, success will depend on differentiated clinical value, access strategy, real-world evidence, patient-centric support, and responsible use of artificial intelligence.

Organizations that combine scientific innovation with affordability, evidence transparency, and scalable care models will be best positioned to lead in ulcerative colitis treatment and long-term inflammatory bowel disease management.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Ulcerative Colitis Market, by Therapy Type

  • 7.1. Aminosalicylates
    • 7.1.1. Mesalamine
    • 7.1.2. Sulfasalazine
  • 7.2. Biologics
    • 7.2.1. Anti Integrins
    • 7.2.2. IL Inhibitors
    • 7.2.3. TNF Inhibitors
      • 7.2.3.1. Infliximab
      • 7.2.3.2. Adalimumab
      • 7.2.3.3. Golimumab
  • 7.3. Corticosteroids
    • 7.3.1. Prednisone
    • 7.3.2. Budesonide
    • 7.3.3. Hydrocortisone
  • 7.4. Immunomodulators
    • 7.4.1. Azathioprine
    • 7.4.2. 6-Mercaptopurine
    • 7.4.3. Methotrexate
  • 7.5. Small Molecule Drugs
    • 7.5.1. Tofacitinib
    • 7.5.2. Upadacitinib
  • 7.6. Surgery

8. Ulcerative Colitis Market, by Route of Administration

  • 8.1. Injectable
    • 8.1.1. Intravenous
    • 8.1.2. Subcutaneous
  • 8.2. Oral
  • 8.3. Topical

9. Ulcerative Colitis Market, by Type

  • 9.1. Ulcerative Proctitis
  • 9.2. Proctosigmoiditis
  • 9.3. Left-Sided Colitis
  • 9.4. Extensive Colitis

10. Ulcerative Colitis Market, by Line Of Therapy

  • 10.1. First Line
  • 10.2. Second Line
  • 10.3. Third Line & Beyond

11. Ulcerative Colitis Market, by Disease Severity

  • 11.1. Mild
  • 11.2. Moderate
  • 11.3. Severe

12. Ulcerative Colitis Market, by Patient Type

  • 12.1. Adult
  • 12.2. Pediatric

13. Ulcerative Colitis Market, by Distribution Channel

  • 13.1. Offline Pharmacy
  • 13.2. Online Pharmacy

14. Ulcerative Colitis Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Ulcerative Colitis Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Ulcerative Colitis Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. AbbVie Inc.
  • 18.2. Abivax SA
  • 18.3. Ajinomoto Pharmaceuticals Co., Ltd.
  • 18.4. Amgen Inc.
  • 18.5. Apotex Inc.
  • 18.6. AstraZeneca plc
  • 18.7. Bausch Health Companies Inc.
  • 18.8. Biocon Limited
  • 18.9. Boehringer Ingelheim GmbH
  • 18.10. Bristol-Myers Squibb Company
  • 18.11. Celltrion, Inc.
  • 18.12. Dr. Falk Pharma GmbH
  • 18.13. EA Pharma Co., Ltd.
  • 18.14. Eli Lilly and Company
  • 18.15. F. Hoffmann-La Roche AG
  • 18.16. Ferring International Center S.A.
  • 18.17. Fresenius Kabi AG
  • 18.18. Galapagos NV
  • 18.19. Gilead Sciences Inc.
  • 18.20. Janssen Biotech, Inc. by Johnson & Johnson
  • 18.21. Merck & Co., Inc.
  • 18.22. Novartis AG
  • 18.23. Pfizer Inc.
  • 18.24. Samsung Bioepis Co., Ltd.
  • 18.25. Sandoz International GmbH
  • 18.26. Sanofi S.A.
  • 18.27. Sun Pharmaceutical Industries Ltd.
  • 18.28. Takeda Pharmaceutical Company Limited
  • 18.29. Viatris Inc.
  • 18.30. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ULCERATIVE COLITIS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ULCERATIVE COLITIS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ULCERATIVE COLITIS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ULCERATIVE COLITIS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ULCERATIVE COLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ULCERATIVE COLITIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ULCERATIVE COLITIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ULCERATIVE COLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AMINOSALICYLATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AMINOSALICYLATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AMINOSALICYLATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MESALAMINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MESALAMINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MESALAMINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SULFASALAZINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SULFASALAZINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SULFASALAZINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI INTEGRINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTI INTEGRINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI INTEGRINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IL INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IL INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IL INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TNF INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TNF INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INFLIXIMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFLIXIMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INFLIXIMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ADALIMUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ADALIMUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ADALIMUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GOLIMUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GOLIMUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GOLIMUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PREDNISONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PREDNISONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PREDNISONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BUDESONIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BUDESONIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BUDESONIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HYDROCORTISONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HYDROCORTISONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HYDROCORTISONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AZATHIOPRINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AZATHIOPRINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AZATHIOPRINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL 6-MERCAPTOPURINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL 6-MERCAPTOPURINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL 6-MERCAPTOPURINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL METHOTREXATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL METHOTREXATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL METHOTREXATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TOFACITINIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TOFACITINIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TOFACITINIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL UPADACITINIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL UPADACITINIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL UPADACITINIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SURGERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SURGERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ULCERATIVE PROCTITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ULCERATIVE PROCTITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ULCERATIVE PROCTITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PROCTOSIGMOIDITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PROCTOSIGMOIDITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PROCTOSIGMOIDITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL LEFT-SIDED COLITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL LEFT-SIDED COLITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL LEFT-SIDED COLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL EXTENSIVE COLITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL EXTENSIVE COLITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL EXTENSIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL FIRST LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL FIRST LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL FIRST LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL SECOND LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SECOND LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL SECOND LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL THIRD LINE & BEYOND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL THIRD LINE & BEYOND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL THIRD LINE & BEYOND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL MILD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL MILD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL MILD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL MODERATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL MODERATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL MODERATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL SEVERE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL SEVERE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL SEVERE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL OFFLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL OFFLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL OFFLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE ULCERATIVE COLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA ULCERATIVE COLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN ULCERATIVE COLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. GCC ULCERATIVE COLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. GCC ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 242. GCC ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 243. GCC ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 244. GCC ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 245. GCC ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 246. GCC ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 247. GCC ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. GCC ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 249. GCC ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. GCC ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. GCC ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 252. GCC ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. GCC ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS ULCERATIVE COLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 284. G7 ULCERATIVE COLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 285. G7 ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. G7 ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 287. G7 ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 288. G7 ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 289. G7 ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 290. G7 ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 291. G7 ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 292. G7 ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 293. G7 ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 294. G7 ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. G7 ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 296. G7 ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 297. G7 ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. G7 ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 299. NATO ULCERATIVE COLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 300. NATO ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. NATO ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 302. NATO ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 303. NATO ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 304. NATO ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 305. NATO ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 306. NATO ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 307. NATO ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 308. NATO ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 309. NATO ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. NATO ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 311. NATO ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 312. NATO ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. NATO ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 314. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 330. CANADA ULCERATIVE COLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 331. CANADA ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. CANADA ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 333. CANADA ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 334. CANADA ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 335. CANADA ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 336. CANADA ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 337. CANADA ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 338. CANADA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 339. CANADA ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 340. CANADA ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 341. CANADA ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 342. CANADA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 343. CANADA ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 344. CANADA ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 345. MEXICO ULCERATIVE COLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 346. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 347. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 348. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 349. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 350. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 351. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 352. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 353. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 354. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 355. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 356. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 357. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 358. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 359. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 360. BRAZIL ULCERATIVE COLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 361. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 362. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 363. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 364. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 365. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 366. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 367. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 368. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 369. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 370. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)

TABL